

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**KELUN-BIOTECH**  
**科伦博泰**

**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**

**四川科倫博泰生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6990)**

## **NOTICE OF BOARD MEETING**

The board of directors (the “**Board**”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “**Company**”) hereby announces that a meeting of the Board will be held on Monday, 19 August 2024 for the purpose of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended 30 June 2024 and its publication, and transacting other business.

By order of the Board  
**Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.**  
**LIU Gexin**  
*Chairman of the Board and Non-executive Director*

Hong Kong, 7 August 2024

*As at the date of this announcement, the board of directors of the Company comprises Mr. LIU Gexin as the chairman of the Board and non-executive director, Dr. GE Junyou as executive director, Mr. LIU Sichuan, Mr. LAI Degui, Mr. FENG Hao, Mr. ZENG Xuebo and Mr. LI Dongfang as non-executive directors, and Dr. ZHENG Qiang, Dr. TU Wenwei, Dr. JIN Jinping, and Dr. LI Yuedong as independent non-executive directors.*